Navigation Links
Neupro® (Rotigotine) Provided Clinically Relevant Improvements in Health-Related Quality of Life for People with Parkinson's Disease
Date:9/30/2010

BRUSSELS, Sept. 30 /PRNewswire/ -- People with Parkinson's disease who used once-daily Neupro® (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms.

Data presented this week at the 2nd World Parkinson Congress in Glasgow, UK, showed that Neupro® provided clinically relevant improvements in PDQ-8 score. This is a self-administered health-related quality of life questionnaire (HRQL) for Parkinson's disease comprising eight items – mobility, activities of daily living, emotional well-being, social support, cognition, communication, bodily discomfort and stigma.

"Data from the RECOVER trial demonstrated improvements in motor and non-motor symptoms for people living with Parkinson's disease as well as worthwhile changes in the quality of their everyday lives, including their daily activities, their emotional well being and their cognitive and communication abilities," said Herve Lilliu, Head of Health Outcomes and Access, UCB.

The RECOVER trial was a multicenter, multinational, double-blind, placebo-controlled study designed to assess the effects of rotigotine in controlling early morning motor function and non-motor symptoms that affect the everyday lives of people with early- and late-stage Parkinson's disease. Patients were randomized (2:1) to receive rotigotine (2-16 mg/24 h) or placebo during a titration period lasting up to 8 weeks, followed by a 4-week maintenance period.

PDQ-8 data were obtained from measurements taken at baseline and at the end of the 12 week study from 89 placebo- and 176 rotigotine-randomized patients. Mean change from baseline PDQ-8 total score was greater in the rotigotine group (-6.9 [SD: 11.9]) than the placebo group (-1.2 [SD: 13.7]; p<0.001). Both the rotigotine effect size (-0.41) and standardized response mean (-0.58) were moderate based on the Cohen definition of change (0.20 sm
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
2. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
5. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
6. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
7. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
8. Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
9. Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
10. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52 Weeks
11. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015 HeartWare International, Inc . ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... President and Chief Executive Officer, Doug Godshall , ... Annual Growth Conference at 8:30 a.m. EDT on Thursday, ... 12-13, 2015 at the InterContinental Boston. A ...
(Date:8/4/2015)... , Aug. 4, 2015 Levi & Korsinsky ... ("Biogen" or the "Company") (NASDAQGS: BIIB) for possible violations ... and certain of its officers and/or directors have violated ... of 1934.  On Friday, July 24, 2015, prior to ... quarter 2015 financial results. Among other things, the Company ...
(Date:8/4/2015)... CARLSBAD, Calif., Aug. 4, 2015  Isis Pharmaceuticals, Inc. ... $35.6 million and $18.9 million for the three and ... a net loss of $12.1 million and $43.4 million ... financial results were driven primarily by the more than ... quarter related to the upfront payment from Bayer to ...
Breaking Medicine Technology:HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Biogen Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws -- BIIB 2Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16
... Endo Pharmaceuticals (Nasdaq: ENDP ) today announced that ... overview at the Stifel Nicolaus Annual Healthcare Conference on Thursday, ... be held at the Four Seasons Hotel in Boston, MA. ... presentation will be available on the company,s website at ...
... (NASDAQ: STXS ) today announced that executive management ... held September 7-9, 2011 in Boston, MA.  Michael P. Kaminski, ... present an overview of the Company on Wednesday, September 7, ... webcast and subsequent archived replay of the presentation will be ...
Cached Medicine Technology:Stereotaxis to Present at the Stifel Nicolaus Healthcare Conference on September 7, 2011 2Stereotaxis to Present at the Stifel Nicolaus Healthcare Conference on September 7, 2011 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... Healthy Origins® Cognizin® is a trademark for Citicoline, a nutrient that supports ... capsule for those applications which have more of a semi-solid composition. Vegetarian ...
(Date:8/4/2015)... ... 04, 2015 , ... It’s hard to look your best, ... in Santa Barbara, CA is offering the solution by offering an underarm sweat-removing ... and odor glands in the underarms. This simple and permanent solution usually offers ...
(Date:8/4/2015)... ... August 04, 2015 , ... Recent ... have shown a rise in binge drinking among certain populations and ... depression, are continuing to examine trends and evidence to help facilitate health care ...
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is worth ... conditions, pictures and medical art can be essential. StayWell, a health solutions company, announced ... Patient Education solutions have been used by physicians and other health care providers for ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... solutions, today announced that Bruce McCalley joins its executive leadership team as Senior ... of sales success at technology companies and expanding global markets with a special ...
Breaking Medicine News(10 mins):Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3
... time for cancer patients in Ontario for radiation has fallen, ... need//. These were the results of a study released by ... Ontario has reported that the system quality index launched last ... radiation treatment to 4.7 weeks, from seven weeks in 2002. ...
... study conducted by Dr. Martina Stippler it was found that ... brain injury//. A team at the University Of Pittsburgh Brain ... patients with severe brain injuries. The study results were presented ... Surgeons in San Francisco. ,The results show that ...
... has revealed the possibilities for the development of a ... well as reversible within a few months of discontinuing ... present are limited to condoms, vasectomy and withdrawal. ... either unreliable or as in the case of vasectomy, ...
... (FDA) has categorically ruled out endorsing the use of ... of Medicine report in 1999, which had said that ... conditions like AIDS wasting, chemotherapy induced nausea and vomiting ... statement issued on Thursday, the FDA stated that "no ...
... cancers that results in death among the Britons. This ... tablet// called Xeloda have only been given to NHS ... of Health and Clinical Excellence (NICE) issued guidance recommending ... had cancerous tissue removed at an early stage. Hence ...
... advice of central government, the Madhya Pradesh government banned ... by vets, saying that it was responsible// for 95 ... vultures are indispensable natural scavengers responsible for the disposal ... of epidemics. But when they themselves feed on animals ...
Cached Medicine News:Health News:Chemotherapy Queues in Ontario Stay Steady 2Health News:Male Contraceptives-Soon to be Reliable and Reversible 2
... Freedom leg bags are part ... a versatile line of leg bags, ... the varied needs of our customers. ... several sizes, and constructed of 100% ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... line of Personal Catheters® ... you would choose for ... configurations - standard, antibacterial, ... - are based on ...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
Medicine Products: